Screener
Avalo Therapeutics AVTX Common Stock Shares Issued
Common Stock Shares Issued at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CommonStockSharesIssued.
The source filing: Avalo Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001534120-26-000049
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Series D Preferred Stock—$0.001 par value; 0 and 1 share of Series D Preferred Stock authorized at June 30, 2026 and December 31, 2025, respectively; 0 and 1 share of Series D Preferred Stock issued and outstanding at June 30, 2026 and December 31, 2025, respectively | — | — |
| Series E Preferred Stock—$0.001 par value; 0 and 1 share of Series E Preferred Stock authorized at June 30, 2026 and December 31, 2025, respectively; 0 and 1 share of Series E Preferred Stock issued and outstanding at June 30, 2026 and December 31, 2025, respectively | — | — |
| Stockholders’ equity: | ||
| Common stock—$0.001 par value; 200,000,000 shares authorized at June 30, 2026 and December 31, 2025; 52,900,692 and 18,512,757 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | 53 | 18 |
| Series C Preferred Stock—$0.001 par value; 4,085 and 34,326 shares of Series C Preferred Stock authorized at June 30, 2026 and December 31, 2025, respectively; 4,085 and 18,792 shares of Series C Preferred Stock issued and outstanding at June 30, 2026 and December 31, 2025, respectively | — | — |
| Series C-1 Preferred Stock—$0.001 par value; 4,295 and 0 shares of Series C-1 Preferred Stock authorized at June 30, 2026 and December 31, 2025, respectively; 4,295 and 0 shares of Series C-1 Preferred Stock issued and outstanding at June 30, 2026 and December 31, 2025, respectively | — | — |
| Additional paid-in capital | 953,700 | 531,485 |
| Accumulated other comprehensive (loss) income | (583) | 68 |
Item 1. Financial Statements.
FAQ
- What is Avalo Therapeutics's common stock shares issued?
- Avalo Therapeutics (AVTX) reported common stock shares issued of 52.9M in Q2 2026.
- How has Avalo Therapeutics's common stock shares issued changed year-over-year?
- Avalo Therapeutics's common stock shares issued increased by 388.1% year-over-year, from 10.8M to 52.9M.
- What is the long-term trend for Avalo Therapeutics's common stock shares issued?
- Over 5 years (2020 to 2025), Avalo Therapeutics's common stock shares issued has grown at a -24.4% compound annual growth rate (CAGR), from 75M to 18.5M.
- What does common stock shares issued mean?
- The total number of shares that have been authorized and distributed by the corporation since its inception. This includes shares held by the public (outstanding) as well as any shares that the company has repurchased and holds in its treasury. It represents the historical volume of equity capital creation.
Ask your AI about Avalo Therapeutics's common stock shares issued.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude